Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody

Triple-negative breast cancer (TNBC) is an aggressive disease with poor prognosis and limited therapeutic options. Recent advances in the immunotherapy field have enabled the development of new treatment strategies, among which the use of bispecific antibodies (BsAbs), able to redirect T cells again...

Descripción completa

Detalles Bibliográficos
Autores principales: Martini, Silvia, Figini, Mariangela, Croce, Aurora, Frigerio, Barbara, Pennati, Marzia, Gianni, Alessandro Massimo, De Marco, Cinzia, Daidone, Maria Grazia, Argueta, Christian, Landesman, Yosef, Zaffaroni, Nadia, Satta, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599683/
https://www.ncbi.nlm.nih.gov/pubmed/33023194
http://dx.doi.org/10.3390/cells9102231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599683/
https://www.ncbi.nlm.nih.gov/pubmed/33023194
http://dx.doi.org/10.3390/cells9102231

Ejemplares similares